EXIST-1 Trial Publishes long term safety data of new treatments for Tuberous Sclerosis
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial (Online release) Released online this week, the EXIST-1 team have published long term safety data of the … Read More